Overview

Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)

Status:
Active, not recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Combination With Adalimumab in Subjects with Moderate to Severe Ulcerative Colitis.

Phase:

Phase 2

Details

Lead Sponsor:

Applied Molecular Transport

Treatments:

Adalimumab